Differential effect of isotype on efficacy of anti-tumor necrosis factor alpha chimeric antibodies in experimental septic shock

doi:10.1084/jem.179.3.849

This Article

	Full Text (PDF, 731K)
	Alert me when this article is cited
	Citation Map

Services

	Email this article
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new content in the JEM
	Download to citation manager

Citing Articles

	Citing Articles via HighWire
	Citing Articles via CrossRef
	Citing Articles via Google Scholar

Google Scholar

	Articles by Suitters, A. J.
	Articles by Chaplin, L. C.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Suitters, A. J.
	Articles by Chaplin, L. C.


Social Bookmarking

	What's this?

ARTICLES

Differential effect of isotype on efficacy of anti-tumor necrosis factor alpha chimeric antibodies in experimental septic shock

AJ Suitters, R Foulkes, SM Opal, JE Palardy, JS Emtage, M Rolfe, S Stephens, A Morgan, AR Holt and LC Chaplin
Celltech, Slough, Berkshire, United Kingdom.

Immune complexes containing human gamma (g)1 or murine g2a antibodies generate secondary effector mechanisms via Fc receptor binding or complement activation, whereas those containing human g4 or murine g1 antibodies generally do not. Therefore, isotype selection of therapeutic antibodies may have important clinical consequences. In a rabbit model of human tumor necrosis factor (rhuTNF)-induced pyrexia, a murine/human chimeric g4 anti-human TNF-alpha monoclonal antibody (mAb) (cCB0011) showed a dose-dependent inhibition of pyrexia, whereas a g1 isotype variant of the same mAb gave a marked pyrexia that was seen at all doses indicative of an immune complex-mediated response. To investigate whether isotype difference could influence mAb efficacy in pathological disease states, hamster/murine chimeric g1 and g2a anti- murine TNF-alpha mAbs (TN3g1, TN3g2a) were studied in experimental shock in mice and rats. In lipopolysaccharide-induced shock in mice, treatment with TN3g1 mAb at 30 and 3 mg/kg resulted in 90% survival by 72 h (p < or = 0.004), and prolonged survival to 45 h (p < or = 0.05), respectively, compared with 100% mortality by 27 h in controls. In contrast, a g2a isotype variant of the same mAb (30 mg/kg) resulted in only 10% survival by 72 h (p < or = 0.05). In a neutropenic sepsis model in rats there was greater survival in animals receiving the g1 isotype of TN3 compared with g2a isotype variant (70 vs. 27%; p < or = 0.005) with 100% mortality in the controls. These differences were not due to the pharmacokinetic profiles of the mAbs. In models of experimental shock antibody isotype can affect outcome with inactive isotypes (human g4 and murine g1) being more efficacious than active isotypes (human g1 and murine g2a).
Add to CiteULike CiteULike Add to Complore Complore Add to Connotea Connotea Add to Del.icio.us Del.icio.us Add to Digg Digg Add to Reddit Reddit Add to Technorati Technorati What's this?

This article has been cited by other articles:

Yrlid, U., Milling, S. W. F., Miller, J. L., Cartland, S., Jenkins, C. D., MacPherson, G. G. (2006). Regulation of Intestinal Dendritic Cell Migration and Activation by Plasmacytoid Dendritic Cells, TNF-{alpha} and Type 1 IFNs after Feeding a TLR7/8 Ligand. J. Immunol. 176: 5205-5212 [Abstract] [Full Text]
Clatworthy, M. R., Smith, K. G.C. (2004). Fc{gamma}RIIb Balances Efficient Pathogen Clearance and the Cytokine-mediated Consequences of Sepsis. JEM 199: 717-723 [Abstract] [Full Text]
Eichacker, P. Q., Parent, C., Kalil, A., Esposito, C., Cui, X., Banks, S. M., Gerstenberger, E. P., Fitz, Y., Danner, R. L., Natanson, C. (2002). Risk and the Efficacy of Antiinflammatory Agents: Retrospective and Confirmatory Studies of Sepsis. Am. J. Respir. Crit. Care Med. 166: 1197-1205 [Abstract] [Full Text]
Truyens, C., Torrico, F., Lucas, R., De Baetselier, P., Buurman, W. A., Carlier, Y. (1999). The Endogenous Balance of Soluble Tumor Necrosis Factor Receptors and Tumor Necrosis Factor Modulates Cachexia and Mortality in Mice Acutely Infected with Trypanosoma cruzi. Infect. Immun. 67: 5579-5586 [Abstract] [Full Text]
Chaudry, I. H. (1999). Sepsis: Lessons Learned in the Last Century and Future Directions. Arch Surg 134: 922-929 [Full Text]
Nguyen, K. B., Biron, C. A. (1999). Synergism for Cytokine-Mediated Disease During Concurrent Endotoxin and Viral Challenges: Roles for NK and T Cell IFN-{gamma} Production. J. Immunol. 162: 5238-5246 [Abstract] [Full Text]
Videla, S., García-Lafuente, A., Antolín, M., Vilaseca, J., Guarner, F., Crespo, E., González, G., Salas, A., Malagelada, J. R. (1998). Antitumor Necrosis Factor Therapy in Rat Chronic Granulomatous Colitis: Critical Dose-Timing Effects on Outcome. J. Pharmacol. Exp. Ther. 287: 854-859 [Abstract] [Full Text]
Miotla, J. M., Teixeira, M. M., Hellewell, P. G. (1998). Suppression of Acute Lung Injury in Mice by an Inhibitor of Phosphodiesterase Type 4�. Am. J. Respir. Cell Mol. Bio. 18: 411-420 [Abstract] [Full Text]
Fisher, C. J., Agosti, J. M., Opal, S. M., Lowry, S. F., Balk, R. A., Sadoff, J. C., Abraham, E., Schein, R. M.H., Benjamin, E., The Soluble TNF Receptor Sepsis Study Group, (1996). Treatment of Septic Shock with the Tumor Necrosis Factor Receptor:Fc Fusion Protein. NEJM 334: 1697-1702 [Abstract] [Full Text]